Furthermore, in patients treated with temozolomide (TMZ), those that had recurrences and had lost methylation of the O(6)-methylguanine-DNA methyl transferase (MGMT) promoter, had increased genetic mutations compared to untreated patients, indicating that this methylation phenotype could contribute to the chemotherapeutic resistance of the tumor (21, 26). Here, MGMT is linked to neoplasm.